Mechanisms of EPO-induced Hypertension
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Indianapolis, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 27 people enrolled
- Started
- 4 Jan 2021
- Ended
- 31 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Darbepoetin
- Record updated
- 15 December 2025
- Why it stopped
- The trial was stopped because of inability to reach target sample size.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Stage 3 or 4 chronic kidney disease
- Controlled hypertension with 24 hour ambulatory blood pressure monitoring less than 140/90 mmHg at baseline and treatment with at least 1 antihypertensive medication
- Hemoglobin between 8 and 10 g/dL
- No treatment with erythropoiesis-stimulating agents (ESA) within 3 previous months
Who cannot take part
- Need for packed red blood cells (RBC) transfusion in the previous 2 months
- Myocardial infarction, stroke or hospitalization for heart failure in the past 2 months
- In the assessment of the investigator, have hematologic, inflammatory, infectious, or other conditions that might interfere with the erythropoietic response
Where in United States
- Richard L. Roudebush VA Medical Center, Indianapolis, INIndianapolis, United States
About the trial
What the trial wants to find out
The investigators hypothesize that compared to untreated controls, erythropoietin (EPO) therapy in anemic patients with chronic kidney disease will raise diastolic blood pressure (BP). The magnitude of increase in diastolic BP at 12 weeks after treatment will be related to two factors. First, endothelial dysfunction and worsening of endothelial function from baseline to 4 weeks and second, the change of forearm blood flow in response to breathing oxygen and the change in this measure from baseline to 4 weeks. Study procedures include fasting blood draws, ambulatory blood pressure, urine collection, and forearm blood flow tests. The study hopes to accrue 160 subjects.
The 2 groups in the trial
- Early startExisting treatment, for comparison
Participants given study drug immediately at randomization
Treatment: Darbepoetin
- Delayed startNo study treatment, for comparison
Participants given study drugs 12 weeks after randomization
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Mechanisms of Erythropoietin Induced Hypertension
- Publications
- Resistant Hypertension in Dialysis: Epidemiology, Diagnosis, and Management.Journal of the American Society of Nephrology : JASN, 2024
- Record updated
- 15 December 2025